FilingsTodayMedtronic
At a glance
Medtronic reported 2025 revenue of $36.36B, up 8.4% from $33.54B in 2024. Over 4 years since 2021 ($31.69B), that is growth of about 3.5% a year. Operating margin was 17.8%, down from 18.2% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 5 insiders reported 0 open-market purchases and 7 sales ($14.7M). 3 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $5.1M by EVP & President Cardiovascular Harry Skip Kiil on Feb 26, 2026.
Medtronic filed 10 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (3), regulation fd disclosure (2) and shareholder vote results (1). The latest officer or director change was reported on Oct 19, 2026.
3 of the 20 investors tracked here held Medtronic at the last quarter end, worth $533M combined. It is the largest weight for Renaissance Technologies (0.3% of its portfolio), followed by National Pension Service (Korea) (0.2%). New this quarter: Renaissance Technologies. Added: National Pension Service (Korea) and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $5,039 | $3,758 | $3,676 | $4,662 | $4,801 |
| Diluted EPS | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 |
| Dividend per share | $2.52 | $2.72 | $2.76 | $2.80 | $2.84 |
Fiscal year ends Apr 24
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined